A new genetic test could spare thousands of breast cancer patients from unnecessary chemotherapy treatments, according to findings from an international clinical trial published in The New England Journal of Medicine. The study suggests that up to 6,600 patients annually in the UK alone could safely avoid the debilitating side effects of chemotherapy while maintaining equivalent survival outcomes.
Chemotherapy Benefit by Genetic Risk Score
5-year survival outcomes in intermediate-risk breast cancer patients, by treatment type
+ hormone therapy
alone
difference
Source: New England Journal of Medicine, 2024 | Georgian Medical Journal News
Genetic Testing Transforms Treatment Decisions
The RxPONDER trial, led by researchers at Montefiore Einstein Comprehensive Cancer Center, analyzed 5,083 breast cancer patients across multiple countries. The study focused on patients with intermediate recurrence scores on the Oncotype DX test, a 21-gene assay that predicts cancer recurrence risk.
Dr. Joseph Sparano, the study’s principal investigator and associate director at Montefiore Einstein Comprehensive Cancer Center, reported that postmenopausal women with intermediate risk scores (11-25) showed no survival benefit from adding chemotherapy to hormone therapy according to the RxPONDER trial findings published in clinical implications.
Among postmenopausal patients in the intermediate-risk group, 5-year survival rates were virtually identical: 93.9% for those receiving chemotherapy plus hormone therapy versus 93.8% for hormone therapy alone, according to the New England Journal of Medicine publication.
Premenopausal Women Show Different Pattern
The RxPONDER study revealed important age-related differences in treatment response. Premenopausal women with intermediate risk scores demonstrated a modest but meaningful benefit from chemotherapy, with improved invasive disease-free survival rates according to the trial results.
According to the American Cancer Society, approximately 287,000 women are diagnosed with invasive breast cancer annually in the United States. Genomic studies have increasingly personalized cancer treatment based on tumor biology rather than traditional staging alone.
Healthcare Systems Prepare for Implementation
Cancer Research UK estimates that implementing this approach could prevent approximately 6,600 patients annually from receiving unnecessary chemotherapy, according to the BBC report.
Postmenopausal women with intermediate recurrence scores showed equivalent 5-year survival rates whether they received chemotherapy plus hormone therapy (93.9%) or hormone therapy alone (93.8%).
— Dr. Joseph Sparano, Montefiore Einstein Comprehensive Cancer Center (New England Journal of Medicine, 2024)
Key takeaways
- Up to 6,600 UK breast cancer patients annually could safely avoid chemotherapy based on genetic testing, according to Cancer Research UK estimates
- Postmenopausal women with intermediate risk scores showed no survival benefit from adding chemotherapy to hormone therapy in the RxPONDER trial
- Premenopausal women in the same risk category still benefit from combination treatment according to the study
- The Oncotype DX 21-gene test analyzed in the RxPONDER trial can guide treatment decisions for intermediate-risk cases
Frequently asked questions
What is the Oncotype DX test and how does it work?
The Oncotype DX test analyzes 21 genes in breast cancer tissue to predict recurrence risk and potential chemotherapy benefit. The RxPONDER trial studied patients with intermediate scores (11-25) on this test.
Will insurance cover genetic testing for breast cancer treatment decisions?
The Oncotype DX test has been available for early-stage breast cancer patients, though specific coverage policies vary by insurer.
How quickly will these findings change standard breast cancer treatment protocols?
The implementation timeline for incorporating these RxPONDER trial findings into clinical practice will vary by healthcare institution.
The RxPONDER trial results published in The New England Journal of Medicine represent findings toward more individualized breast cancer treatment that could spare thousands of patients from unnecessary side effects while maintaining optimal outcomes.
Source: Millions of breast cancer patients could safely avoid chemotherapy, study suggests
Was this article helpful?
100% of readers found this helpful (1 votes)
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
